Direct-to-Consumer advertising of pharmaceuticals as a matter of corporate social responsibility?

Journal of Business Ethics

Volumn 94, Issue 2, 2010, Pages 211-224

  van de Pol, Pepijn K C ^a   de Bakker, Frank G A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Consumer safety; Corporate social responsibility (CSR); Direct to consumer advertising (DTCA); Pharmaceutical industry

Indexed keywords

EID: 77954174897     PISSN: 01674544     EISSN: 15730697     Source Type: Journal    
DOI: 10.1007/s10551-009-0257-z     Document Type: Article

References (70)

1. ACP (American College of Physicians): 2005, Statement of the American College of Physicians, for the Record of the Public Hearing on "Consumer-Directed Promotion of Regulated Medical Products". Department of Health and Human Services Food and Drug Administration, November 1-2, 2005.
2. ACP/ASIM (American College of Physicians-American Society of Internal Medicine): 1998, Direct to Consumer Advertising for Prescription Drugs, 9 October 1998, http://www. acponline. org/hpp/pospaper/dtcads. htm. Accessed October 2008.
3. Almasi, E. A., Stafford, R. S., Kravitz, R. L., & Mansfield, P. R. 2006. What are the public health effects of direct-to-consumer drug advertising? PLoS Medicine, 3(3): 284-288.
4. Angel, M. D. 2000. The pharmaceutical industry - to whom is it accountable? New England Journal of Medicine, 342(25): 1902-1904.
5. Attaran, A. 2004. How do patents and economic policies affect access to essential medicines in developing countries? Health Affairs, 23(3): 155-166.
6. Auton, F. 2006. Direct-to-consumer advertising (DTCA) of pharmaceuticals: An updated review of the literature and debate since 2003. Economic Affairs, 26(3): 24-32.
7. Auton, F. 2007. The patient as consumer: The advertising of pharmaceuticals directly to consumers should be allowed and encouraged. Economic Affairs, 27(2): 64-72.
8. Beltramini, R. F. 2006. Consumer believability of information in direct-to-consumer (DTC) advertising of prescription drugs. Journal of Business Ethics, 63: 333-343.
9. Berger, J. T., Kark, P., Rosner, F., Packer, S., & Bennett, A. J. 2001. Direct-to-consumer drug marketing: Public service or disservice? Mount Sinai Journal of Medicine, 68: 197-202.
10. Berry, M. A. and D. A. Rondinelli: 2000, Environmental Management in the Pharmaceutical Industry: Integrating Corporate Responsibility and Business Strategy. Environmental Quality Management (Spring), 21-35.
11. Blum-Kusterer, M., & Hussain, S. S. 2001. Innovation and corporate sustainability: An investigation into the process of change in the pharmaceuticals industry. Business Strategy and the Environment, 10: 300-316.
12. Buckley, J. 2004. Pharmaceutical marketing - time for change. Electronic Journal of Business Ethics and Organization Studies, 9(2): 4-11.
13. Carroll, A. B. 1999. Corporate Social Responsibility: Evolution of a definitional construct. Business & Society, 38: 268-295.
14. Cheah, E. T., Chan, W. L., & Chieng, C. L. L. 2007. The corporate social responsibility of pharmaceutical product recalls: An empirical examination of US and UK markets. Journal of Business Ethics, 76: 427-449.
15. Cline, R. J. W., & Young, H. N. 2004. Marketing drugs, marketing health care relationships: A content analysis of visual cues in direct-to-consumer prescription drug advertising. Health Communication, 16(2): 131-157.
16. de Bakker, F. G. A., Groenewegen, P., & den Hond, F. 2005. A bibliometric analysis of 30 years of research and theory on corporate social responsibility and corporate social performance. Business & Society, 44(3): 283-317.
17. de Laat, E., Windmeijer, F, & Douven, R. C. M. H. 2002. How does pharmaceutical marketing influence doctors' prescribing behaviour?. Den Haag: CPB.
18. den Hond, F., de Bakker, F. G. A., Neergaard, P., & Gond, J. P. 2007. Managing corporate social responsibility in action: Reconciling rhetorical harmony and practical dissonance. In: den Hond, F., de Bakker, F. G. A., & Neergaard, P. (eds.). Managing corporate social responsibility in action: Talking, doing and measuring. Aldershot, Ashgate: 205-223.
19. Desselle, S. P., & Aparasu, R. 2000. Attitudinal dimensions that determine pharmacists' decisions to support DTCA of prescription medication. Drug Information Journal, 34(1): 103-114.
20. Devlin, E., Hastings, G., Smith, A., McDermott, L., & Noble, G. 2007. Pharmaceutical marketing: a question of regulation. Journal of Public Affairs, 7(2): 135-147.
21. Dubois, R. W.: 2003, 'Pharmaceutical Promotion: Don't Throw the Baby Out with the Bathwater', Health Affairs - Web Exclusive W3-96-W3-103, http://content. healthaffairs. org/cgi/reprint/hlthaff. w3. 96v1. pdf. Accessed September 2007.
22. EFPIA (European Federation of Pharmaceutical Industries and Associations): 1993, 'European Code of Practice for the Promotion of Medicines', http://www. efpia. org. Accessed April 2004.
23. EFPIA (European Federation of Pharmaceutical Industries and Associations): 2009, 'EFPIA Position Paper on Commission's Proposal on Patient Information', http://www. efpia. eu/content/default. asp?PageID=559& DocID=6108. Accessed July 2009.
24. Elliot, S.: 2002, 'The Fight to Keep "Direct-to-Consumer Ads"', New York Times, July 12.
25. EMEA (European Medicines Evaluation Agency): 2009, 'Human Medicines', http://www. emea. europa. eu/index/indexh1. htm. Accessed July 2009.
26. Euractiv. com: 2008, 'EU to Ease Drugs Ad Rules in Upcoming Pharma Package', http://www. euractiv. com/en/health/eu-ease-drugs-ad-rules-upcoming-pharma-package/article-174648. Accessed September 2008.
27. European Commission: 2004, Directive 2001/83/EC, November 6, 2001, As Amended by Directive 2004/27/EC, March 31, 2004.
28. Fabius, A. M., Cheung, K.-C., Rijcken, C. J. F., Vinkers, C. H., & Talsma, H. 2004. Direct-to-consumer communication on prescription only medicines via the Internet in the Netherlands, a pilot study. Opinion of the pharmaceutical industry, patient associations and support groups. Pharmacy World & Science, 26(3): 169-172.
29. FDA (Food and Drugs Administration): 1999, 'Guidance for Industry: Consumer Directed Broadcast Advertisements', http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070065. pdf. Accessed July 2009.
30. Fisher, J. A., & Ronald, L. M. 2008. Direct to consumer responsibility: Medical neoliberalism in pharmaceutical advertising and drug development. Patients, Consumers and Civil Society, 10: 29-51.
31. Friedman, M., & Gould, J. 2007. Consumer attitudes and behaviors associated with direct-to-consumer prescription drugs marketing. Journal of Consumer Marketing, 24: 100-109.
32. Gagnon, M. A., & Lexchin, J. 2008. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine 5(1): 29-33.
33. Garriga, E., & Melé, D. 2004. Corporate social responsibility theories: Mapping the territory. Journal of Business Ethics, 53: 51-71.
34. Gilbody, S., Wilson, P., & Watt, I. 2005. Benefits and harms of direct to consumer advertising: A systematic review. Quality and Safety in Healthcare, 14: 246-250.
35. Gordon, K.: 2001, The OECD Guidelines and Other Corporate Responsibility Instruments: A Comparison (OECD, Paris). Working Papers on International Investment No. 2001/5.
36. Griffiths, J. 2003. The social working of legal rules. Journal of Legal Pluralism, 48: 1-84.
37. Guthrie, P. 2007. Direct-to-consumer advertising debated in the United States and European Union. Canadian Medical Association Journal 176(10): 1404.
38. Harland, D. 1987. The United Nations guidelines for consumer protection. Journal of Consumer Policy, 10(3): 245-266.
39. Hollon, M. F. 1999. Direct-to-consumer marketing of prescription drugs: Creating consumer demand. Journal of the American Medical Association, 281(4): 382-384.
40. Holstein, W. J. 2006. 'The Impact of Image on the Bottom Line', New York Times, April 9, 2006. Section 3: 13.
41. Kaphingst, K. A., DeJong, W., Rudd, R. E., & Daltroy, L. H. 2004. A content analysis of direct-to-consumer television prescription drug advertisements. Journal of Health Communication, 9(6): 515-528.
42. Lee, M. D. P. 2007. A review of the theories of corporate social responsibility: Its evolutionary path and the road ahead. International Journal of Management Reviews, 10(1): 53-73.
43. Leisinger, P. K. 2005. The corporate social responsibility of the pharmaceutical industry: Idealism without illusion and realism without resignation. Business Ethics Quarterly, 15: 577-594.
44. Lucas, J. R. 1993. Responsibility. Oxford, Clarendon Press.
45. Magrini, N., & Font, M. 2007. Direct to consumer advertising o drugs in Europe. Evidence on Its benefits and harms is available but is being ignored, British Medical Journal, 335: 526.
46. Maignan, I. & Ferrell, O. C. 2004. Corporate social responsibility and marketing: An integrative framework. Journal of the Academy of Marketing Sciences, 32(1): 3-19.
47. Maloni, M. J., & Brown, M. E. 2006. Corporate social responsibility in the supply chain: An application in the food industry. Journal of Business Ethics, 68(1): 35-52.
48. Medawar, C. 2002. Promotion of prescription drugs: Trade tactics? Consumer Policy Review, 12 (1): 18-30.
49. Meier, B.: 2008, 'Consumer Ads for Medical Devices Subject of Senate Panel', New York Times, September 17.
50. Mello, M. M., Rosenthal, M., & Neumann, P. J. 2003. Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers. Journal of the American Medical Association, 289(4): 477-481.
51. Mintzes, B. 2006. Direct-to-Consumer Advertising of Prescription Drugs in Canada. What are the Public Health Implications?. Toronto: Health Council of Canada.
52. Norris, P., A. Herxheimer, J. Lexchin and P. Mansfield: 2004, Drug Promotion. What We Know, What We Have Yet to Learn. Reviews of Materials in the WHO/HAI Database on Drug Promotion (World Health Organization, Geneva), http://www. who. int/entity/medicines/areas/rational_use/drugPromodhai. pdf. Accessed September 2007.
53. O'Rourke, J. S. 2006. Merck & Co. Inc.: Communication lessons from the withdrawal of Vioxx. Journal of Business Strategy, 27(4): 11-22.
54. Parker, R. S., & Pettijohn, C. E. 2003. Ethical considerations in the use of direct-to-consumer-advertising and pharmaceutical promotions: The impact on pharmaceutical sales and physicians. Journal of Business Ethics, 48(3): 279-290.
55. Priest, A. 2007. CanWest set to challenge ban on DTCA. Canadian Medical Association Journal, 176(1): 19-20.
56. Resnik, D. B. 2001. Developing drugs for the developing world: An economic, legal, moral, and political dilemma. Developing World Bioethics, 1(1): 11-32.
57. Saunders, B.: 2003, Direct-to-Consumer Advertising - Where Does the Public Interest Lie? Journal of the New Zealand Medical Association 116(1180), http://www. nzma. org. nz/journal/116-1180/557. Accessed October 2007.
58. Sones, M., Grantham, S., & Vieira, E. T. 2009. Communicating CSR via pharmaceutical company websites. Evaluating message frameworks for external and internal stakeholders. Corporate Communications: An International Journal, 14(2): 144-157.
59. Sullivan, R. 2000. Direct to consumer advertising: The future in Europe. Journal of the Royal Society of Medicine, 93(8): 400-401.
60. Toop, L., D. Richards, T. Dowell, M. Tilyard, T. Fraser and B. Arroll: 2003, For Health or for Profit? Report to the Minister of Health, Supporting the Case for a Ban on DTCA New Zealand (University of Otago, Dunedin), http://www. chmeds. ac. nz/report. pdf. Accessed September 2007.
61. United Nations: 1999, United Nations Guidelines for Consumer Protection. Universal Declaration of Human Rights, G. A. res. 217A (III), U. N. Doc A/810 at 71 (1948).
62. van Oosterhout, J. & Heugens, P. P. M. A. R. 2007. Much ado about nothing. A conceptual critique of CSR. In: A. Crane, A. McWilliams, D. Matten, J. Moon & D. Siegel (eds.) Oxford handbook of corporate social responsibility. Oxford, Oxford University Press: 197-224.
63. Vastag, B. 2005. FDA considers tightening regulations for Direct-to-Consumer advertising. Journal of the National Cancer Institute, 97(42): 1806-1807.
64. Vickers, J. 2002. Healthy competition and Its consumer wins. Consumer Policy Review, 12(4): 142-147.
65. Vogel, R. J. 2002. Pharmaceutical patents and price controls. Clinical Therapeutics, 24(7): 1204-1222.
66. Werther, W. B., & Chandler, D. 2006. Strategic corporate social responsibility. Stakeholders in a global environment. Thousand Oaks, Sage.
67. Wilkes, M. S., Bell, R. A., & Kravitz, R. L. 2000. Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Affairs, 19: 110-128.
68. Wyke, A. 2004. Direct-to-consumer (DTC) marketing patient views: DTC advertising. International Journal of Medical Marketing, 4(4): 310-312.
69. Zachry, W. M., Dalen, J. E., & Jackson, T. R. 2003. Clinicians' responses to direct-to-consumer advertising of prescription medications. Archives of Internal Medicine, 163(15): 1808-1812.
70. Zachry W., & Ginsburg, D. 2001. Patient autonomy and the relation of direct to consumer advertising. Clinical Therapeutics, 23(12): 2024-203.